ProfileGDS5678 / 1431121_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 9% 9% 9% 8% 8% 8% 8% 9% 9% 9% 9% 9% 9% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.230819
GSM967853U87-EV human glioblastoma xenograft - Control 22.214069
GSM967854U87-EV human glioblastoma xenograft - Control 32.215789
GSM967855U87-EV human glioblastoma xenograft - Control 42.161378
GSM967856U87-EV human glioblastoma xenograft - Control 52.161158
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.25088
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.214768
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.191329
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.18449
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.201289
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.198849
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.184759
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.207049
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.202229